Deep venous thrombosis (DVT) remains a serious and common complication of surgical procedures and is therefore an issue of importance for all urologists. In the UK, pulmonary embolism (PE) following DVT in hospitalised patients causes 32,000 deaths each year. DVT and PE represent the outcome of venous thromboembolism (VTE). The total cost for management of VTE in 2005 was approximately ₤640 million. Early risk assessment and optimising modifiable risks are paramount in order to reduce the incidence of VTE. In this article we review common risk factors for VTE and emphasise specific risk factors for urological procedures. The perioperative management of urological patients who are chronically anticoagulated is discussed. We review the literature regarding anticoagulation and its relevance to all urological procedures and mention the problems associated with new anticoagulant agents. All urologists should be familiar with the new range of anticoagulant agents due to the increasing number of patients taking them.
CohenATAgnelliGAndersonFA. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost2007; 98: 756–764.
2.
ScarpaRMCarrieriGGussoniG. Clinically overt venous thromboembolism after urologic cancer surgery: Results from the @RISTOS Study. Eur Urol2007; 51: 130–135; discussion 136.
3.
De MartinoRRGoodneyPPSpanglerEL. Variation in thromboembolic complications among patients undergoing commonly performed cancer operations. J Vasc Surg2012; 55: 1035–1040.e4.
4.
ZieglerSSchillingerMMacaTH. Post-thrombotic syndrome after primary event of deep venous thrombosis 10 to 20 years ago. Thromb Res2001; 101: 23–33.
5.
StainMSchönauerVMinarE. The post-thrombotic syndrome: Risk factors and impact on the course of thrombotic disease. J Thromb Haemost2005; 3: 2671–2676.
6.
EberliDChassotPGSulserT. Urological surgery and antiplatelet drugs after cardiac and cerebrovascular accidents. J Urol2010; 183: 2128–2136.
7.
House of Commons Health Committee. The Prevention of venous thromboembolism in hospitalised patients. London: The House of Commons, 2005, p.3.
8.
SchmitgesJTrinhQDSunM. Venous thromboembolism after radical prostatectomy: The effect of surgical caseload. BJU Int2012; 110: 828–833.
VanDlacAACowanNGChenY. Timing, incidence and risk factors for venous thromboembolism in patients undergoing radical cystectomy for malignancy: A case for extended duration pharmacological prophylaxis. J Urol2014; 191: 943–947.
11.
DyerJWykeSLynchC.Hospital Episode Statistics data analysis of postoperative venous thromboembolus in patients undergoing urological surgery: A review of 126,891 cases. Ann R Coll Surg Engl2013; 95: 65–69.
12.
LangfordNStansbyGAvitalL.The management of venous thromboembolic diseases and the role of thrombophilia testing: Summary of NICE Guideline CG144. Acute Med2012; 11: 138–142.
13.
BlanchardJMeuwlyJYLeyvrazPF. Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. J Bone Joint Surg Br1999; 81: 654–659.
14.
National Clinical Guideline Centre for Acute and Chronic Conditions. National Institute for Health and Clinical Excellence (NICE): Guidance. Venous thromboembolism: Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. London: Royal College of Physicians (UK), NICE, 2010.
15.
SoderdahlDWHendersonSRHansberryKL.A comparison of intermittent pneumatic compression of the calf and whole leg in preventing deep venous thrombosis in urological surgery. J Urol1997; 157: 1774–1776.
16.
RosendaalFR.Risk factors for venous thrombotic disease. Thromb Haemost1999; 82: 610–619.
17.
HullRDLiangJBergqvistD. Benefit-to-harm ratio of thromboprophylaxis for patients undergoing major orthopaedic surgery. A systematic review. Thromb Haemost2014; 111: 199–212.
18.
GeertsWHPineoGFHeitJA. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest2004; 126 (3 Suppl): 338s-400s.
19.
Beyer-WestendorfJGelbrichtVForsterK. Peri-interventional management of novel oral anticoagulants in daily care: Results from the prospective Dresden NOAC registry. Eur Heart J2014; 35: 1888–1896.
20.
KeelingDBaglinTTaitC. Guidelines on oral anticoagulation with warfarin – fourth edition. Br J Haematol2011; 154: 311–324.
21.
Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group. BMJ1992; 305: 567–574.
22.
DonatRMancey-JonesB.Incidence of thromboembolism after transurethral resection of the prostate (TURP) – a study on TED stocking prophylaxis and literature review. Scand J Urol Nephrol2002; 36: 119–123.
WeinmeisterKPMuirJJFerrigniRG.Pulmonary thromboembolism during transurethral resection of the prostate. Southern Med J2000; 93: 436–438.
25.
GolashACollinsPWKynastonHG. Venous thromboembolic prophylaxis for transurethral prostatectomy: Practice among British urologists. J R Soc Med2002; 95: 130–131.
26.
DescazeaudARobertGLebdaiS. Impact of oral anticoagulation on morbidity of transurethral resection of the prostate. World J Urol2011; 29: 211–216.
27.
WilsonRGSmithDPatonG. Prophylactic subcutaneous heparin does not increase operative blood loss in transurethral resection of the prostate. Br J Urol1988; 62: 246–248.
28.
BejjaniBBChenDCNolanNG. Minidose heparin in transurethral prostatectomy. Urology1983; 22: 251–254.
29.
SleightMW.The effect of prophylactic subcutaneous heparin on blood loss during and after transurethral prostatectomy. Br J Urol1982; 54: 164–165.
30.
SandhuJSNgCKGonzalezRR. Photoselective laser vaporization prostatectomy in men receiving anticoagulants. J Endourol2005; 19: 1196–1198.
31.
BishopCVLiddellHIschiaJ. Holmium laser enucleation of the prostate: Comparison of immediate postoperative outcomes in patients with and without antithrombotic therapy. Curr Urol2013; 7: 28–33.
32.
KeferJCTurnaBSteinRJ. Safety and efficacy of percutaneous nephrostolithotomy in patients on anticoagulant therapy. J Urol2009; 181: 144–148.
33.
NerliRBReddyMNDevarajuS. Percutaneous nephrolithotomy in patients on chronic anticoagulant/antiplatelet therapy. Chonnam Med J2012; 48: 103–107.
34.
WattersonJDGirvanARCookAJ. Safety and efficacy of holmium: YAG laser lithotripsy in patients with bleeding diatheses. J Urol2002; 168: 442–445.
35.
TurnaBSteinRJSmaldoneMC. Safety and efficacy of flexible ureterorenoscopy and holmium:YAG lithotripsy for intrarenal stones in anticoagulated cases. J Urol2008; 179: 1415–1419.
36.
KuoRLAslanPFitzgeraldKB. Use of ureteroscopy and holmium:YAG laser in patients with bleeding diatheses. Urology1998; 52: 609–613.
37.
KlinglerHCKramerGLoddeM. Stone treatment and coagulopathy. Eur Urol2003; 43: 75–79.
38.
CollinsRScrimgeourAYusufS. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med1988; 318: 1162–1173.
39.
Van HemelrijckMGarmoHHolmbergL. Thromboembolic events following surgery for prostate cancer. Eur Urol2013; 63: 354–363.
40.
MerkowRPBilimoriaKYMcCarterMD. Post-discharge venous thromboembolism after cancer surgery: Extending the case for extended prophylaxis. Ann Surg2011; 254: 131–137.
41.
KakkarAKHaasSWolfH. Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: The MC-4 cancer substudy. Thromb Haemost2005; 94: 867–871.
42.
BlomJWDoggenCJOsantoS. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA2005; 293: 715–722.
43.
ReynardJBrewsterSBiersS.Oxford handbook of urology. Third edition. Oxford: Oxford University Press, 2013.
44.
GuyattGHAklEACrowtherM. Executive summary: Antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012; 141 (2 Suppl): 7s–47s.
45.
National Clinical Guideline Centre for Acute and Chronic Conditions. Venous thromboembolism: Reducing the risk: Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. 15 SURGICAL PATIENTS: Gastrointestinal, gynaecological, thoracic and urological. UK, 2010.
46.
RasmussenMSJørgensenLNWille-JørgensenP. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev2009; 1: CD004318.
47.
BergqvistDAgnelliGCohenAT. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med2002; 34: 975–980.
48.
SunAJDjaladatHSchuckmanA. Venous thromboembolism following radical cystectomy: Significant predictors, comparison of different anticoagulants, and timing of events. J Urol2014; 193: 565–569.
49.
AlbertsBDWolduSLWeinbergAC. Venous thromboembolism after major urologic oncology surgery: A focus on the incidence and timing of thromboembolic events after 27,455 operations. Urology2014; 84: 799–806.
50.
WeinbergAWrightJDeibertC. Nationwide practice patterns for the use of venous thromboembolism prophylaxis among men undergoing radical prostatectomy. World J Urol2014; 32: 1313–1321.
JamesACHoltSKWrightJL. Burden and timing of venothrombolic events in patients younger than 65 years undergoing radical cystectomy for bladder cancer. Urol Oncol2014; 32: 815–819.
53.
PannucciCJBaileySHDreszerG. Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients. J Am Coll Surg2011; 212: 105–112.
54.
HaasSFlosbachCW. Prevention of postoperative thromboembolism with Enoxaparin in general surgery: A German multicenter trial. Semin Thromb Hemost1993; 19 (Suppl 1): 164–173.
55.
NguyenNTOwingsJTGosselinR. Systemic coagulation and fibrinolysis after laparoscopic and open gastric bypass. Arch Surg2001; 136: 909–916.
56.
NguyenNTHinojosaMWFayadC. Laparoscopic surgery is associated with a lower incidence of venous thromboembolism compared with open surgery. Ann Surg2007; 246: 1021–1027.
57.
MontgomeryJSWolfJSJr.Venous thrombosis prophylaxis for urological laparoscopy: Fractionated heparin versus sequential compression devices. J Urol2005; 173: 1623–1626.
58.
SecinFPJibornTBjartellAS. Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy. Eur Urol2008; 53: 134–145.
59.
PalaretiGLealiNCoccheriS. Hemorrhagic complications of oral anticoagulant therapy: Results of a prospective multicenter study ISCOAT (Italian Study on Complications of Oral Anticoagulant Therapy) [article in Italian]. G Ital Cardiol1997; 27: 231–243.
60.
MakrisMVan VeenJJTaitCR. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol2013; 160: 35–46.
61.
SchulmanSCrowtherMA. How I treat with anticoagulants in 2012: New and old anticoagulants, and when and how to switch. Blood2012; 119: 3016–3023.
62.
BaglinTKeelingDKitchenS. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology. Br J Haematol2012; 159: 427–429.
63.
DouketisJDBergerPBDunnAS. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest2008; 133 (6 Suppl): 299s-339s.
64.
OscarssonAGuptaAFredriksonM. To continue or discontinue aspirin in the perioperative period: A randomized, controlled clinical trial. Br J Anaesth2010; 104: 305–312.
65.
CulkinDJExaireEJGreenD. Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper. J Urol2014; 192: 1026–1034.
